@article{0261ae0862a6420190fcc5d434c2d603,
title = "Precision therapy in congenital long QT syndrome",
abstract = "Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.",
keywords = "Genetic testing, Long QT syndrome, Precision therapy, Sudden cardiac death",
author = "Raquel Neves and Sahej Bains and Bos, {J. Martijn} and Ciorsti MacIntyre and Giudicessi, {John R.} and Ackerman, {Michael J.}",
note = "Funding Information: This publication was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (MJA) and the Mayo Clinic Center for Translational Science Activities (CTSA) through grant number UL1TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Funding Information: We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. We confirm that all authors are responsible for the content and have read and approved the manuscript; and that the manuscript conforms to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals published in Annals in Internal Medicine, We understand that the Corresponding Author is the sole contact for the Editorial process. He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. This publication was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (MJA) and the Mayo Clinic Center for Translational Science Activities (CTSA) through grant number UL1TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Dr. Ackerman is a consultant for Abbott, ARMGO Pharma, Boston Scientific, Bristol Myers Squibb, Daichii Sankyo, Invitae, LQT Therapeutics, Medtronic, and UptoDate. MJA and Mayo Clinic are involved in an equity/royalty relationship with AliveCor, Anumana, and Pfizer. However, none of these entities were involved in this study. The other authors have no conflicts to declare. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
doi = "10.1016/j.tcm.2022.06.006",
language = "English (US)",
journal = "Trends in cardiovascular medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
}